swissfillon AG

JERSEY CITY, N.J., Oct. 25, 2023 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Size, Share & Trends Analysis Report By Type of Container (Sterile Cartridges, Sterile Syringes, and Sterile Vials), Type of Closure (Caps, Plungers, Seals, Stoppers, Tip Caps / Needle Shields), Material of Fabrication (Aluminum, Glass, Plastic, and Rubber)-Market Outlook And Industry Analysis 2031." Continue Reading InsightAce Analytic Pvt. Ltd According to the latest research by InsightAce Analytic, the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market size is valued at US$ 8.42 Bn in 2022, and it is expected to reach US$ 14.23 Bn in 2031, recording a promising CAGR of 6.13% during the forecast period of 2023-2031. The primary packaging of drugs and vaccines is important in ensuring their integrity, quality and protecting them from contaminants. Hence, sterilization is essential in pharmaceutical manufacturing because it helps maintain product safety and adhere to strict quality standards. This has increased the importance of pre-sterilized/ready-to-use containers in pharmaceutical packaging. Ready-to-use vials eliminate the need for in-house sterilization processes, reducing contamination risks and production timelines. The surging demand for safe drug delivery systems has enhanced the growth of the Pre-Sterilized/Ready to Use Pharmaceutical packaging market. Recent advances in packaging materials and technologies have resulted in innovative solutions offering high drug compatibility, stability, and barrier properties. The advantages offered by empty sterile vials and syringes, and their increasing demand in the healthcare sector, specifically after the COVID-19 pandemic, have prompted manufacturers to implement advancements that are likely to propel the market growth during the forecast period. Request for Sample Pages: Some of the prominent players in the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market are: ABB Afton Scientific ALK Life Science Solutions Allergy Laboratories AptarGroup Aseptic Technologies Becton Dickinson Berkshire Sterile Manufacturing Bharat Rubber Works BioPharma Solutions Bormioli Pharma Catalent Centor COLANAR Corning Credence MedSystems Daikyo Seiko Dara Pharmaceutical Packaging Datwyler Group DENSO Disposable-Lab (Acquired by Amatsigroup) DWK Life Sciences EMA Pharmaceuticals Amatsigroup (Acquired by Eurofins CDMO) FANUC America GCL Pharma (Acquired by Bormioli Pharma) Gerresheimer Huayi Isotopes Company IMA ISOLAB Jiangsu Hualan New Pharmaceutical Material Kawasaki Heavy Industries Klenzaids Contamination Controls KUKA Marchesini Group MedCision MedicoPack Merck Momentive Technologies Muller + Muller (Acquired by DWK Life Sciences) Nelson Labs Nemera Ningbo Zhengli Pharmaceutical Packaging Nipro OMRON Industrial Automation Origin Pharma Packaging Ott (Acquired by Datwyler Group) Pall Pfeiffer Vacuum Pfizer Philabundance Prince Sterilization Services Qingdao Huaren Medical Product Radpharm Scientific Retractable Technologies Sagar Rubber Samsung Medical Rubber Sartorius SCHOTT Seiko Epson SGD Pharma SiO2 Materials Science Sonata Rubber Staubli Steriline Sterisets International Stevanato Group SureCare SVM Automatik Swissfillon Syntegon Tekpak Terumo Toxikon Europe (Acquired by Sterigenics International) Transcoject Triveni Polymers (Acquired by Gerresheimer) Universal Medicap Universal Robots United Pharmacy Partners (UPPI) Vaccines Manufacturing and Innovation Centre Vanrx Pharmasystems Vetter Pharma VIGHNESH Rubbers Watson-Marlow Fluid Technology Group West Pharmaceutical Services YangZhong Wealth Metal Yaskawa Electric Ypsomed Curious about this latest version of the report? Enquiry Before Buying: Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Report Scope Market Dynamics: Drivers: The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products. In addition, strict regulatory guidelines set by regulatory agencies such as the FDA and EMA play an essential role in booming the demand for pre-sterilized pharmaceutical packaging. Moreover, the complex manufacturing of advanced therapies such as cell and gene therapies led to a surge in the need for suitable containers for ATMP aseptic filling & finishing. The addition of RTU (ready-to-use) packaging into the pharmaceutical industry ensures that the product is quickly available through the optimized supply chain. Further, the high demand for COVID-19 vaccines has boosted market growth, especially for sterile vials. Regional Trends: North America captured the highest revenue share of the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market in 2022 and is expected to continue its growth during the forecast period 2023-2031. This growth can be attributed to the increasing demand for pharmaceutical products, well-developed healthcare infrastructure, and rising government efforts and investments in developing pharmaceutical facilities. Besides, the Asia Pacific region is anticipated to grow faster in the next few years. Key developments in the market: In June 2022, Schott invested multi-Bn euros to increase sterile RTU vials production at its facility in Pennsylvania, US. In March 2022, Stevanato expanded its vial manufacturing operations to meet the need for vaccines during the pandemic under a contract with the Biomedical Advanced Research and Development Authority (BARDA). The company has invested in expanding the production capacity for both standard RTU vials and EZ fill RTU vials. In March 2022, SGD Pharma introduced a 100 ml ready-to-use sterile glass vial, catering to the demand for small and large sterile vials. Market Segments Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Container Sterile Cartridges Sterile Syringes Sterile Vials Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Closure Caps Plungers Seals Stoppers Tip Caps / Needle Shields Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Material of Fabrication Aluminum Glass Rubber Plastic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region North America Europe Asia Pacific Latin America Middle East & Africa North America Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 U.S. Canada Europe Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 Germany France Italy Spain Russia Rest of Europe Asia Pacific Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 India China Japan South Korea Australia & New Zealand Latin America Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 Brazil Mexico Rest of Latin America Middle East & Africa Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 GCC Countries South Africa Rest of Middle East & Africa Obtain Report Customization Details @ Why should buy this report: To receive a comprehensive analysis of the prospects for the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market To receive an industry overview and future trends in the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market To analyze the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market drivers and challenges To get information on the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market size value (US$ Mn) forecast till 2031 Major Investments, Mergers & Acquisitions in the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market industry Other Related Reports Published by InsightAce Analytic: Pharmaceutical Packaging Market Research Report 2023 Sustainable Pharmaceutical Packaging Market Research Report 2023 Pharmaceutical Plastic Bottles Market Research Report 2023 About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ Logo - SOURCE InsightAce Analytic Pvt. Ltd

- Establishes Fiscal 2023 Guidance - PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2022, and established fiscal 2023 guidance. Fourth Quarter and Full Year 2022 Highlights (compared with the same periods last year) Fourth quarter revenue increased 26% to €292.1 million, diluted EPS were €0.18, and adjusted diluted EPS were €0.19. Adjusted EBITDA margin was 28%. Fiscal year 2022 revenue grew 17% to €983.7 million, diluted EPS were €0.54, and adjusted diluted EPS were €0.56. Adjusted EBITDA margin was 26.8%. Revenue from high value solutions was approximately 30% of total revenue for both the fourth quarter and the full year. Committed backlog increased 9% to approximately €957 million and, excluding Covid-19, increased 21%. The Company is establishing full year 2023 guidance of revenue in the range of €1.085 billion to €1.115 billion, adjusted diluted EPS between €0.58 and €0.62, and adjusted EBITDA in the range of €290.5 million to €302.5 million. Fourth Quarter Results Revenue for the fourth quarter of 2022 increased 26% to €292.1 million (approximately 23% on a constant currency basis), compared with the same period last year, driven by growth in both of the Company's business segments, the shift to high value solutions, and favorable foreign currency translation. Top-line results for the fourth quarter were better than expected due to the timing of revenue that was previously forecasted in Q1 2023. This includes revenue from certain Engineering projects and Covid-19. As a result, revenue from Covid-19 represented approximately 12% of total revenue. As expected, revenue from high value solutions increased to 30% of total revenue for the fourth quarter. For the fourth quarter of 2022, gross profit margin increased 290 basis points to 34.3% driven by higher revenue, the mix shift to high value solutions, better leverage of fixed costs, and the recovery of inflationary costs, while operating profit margin of 21.6% included a benefit of €3.0 million related to a joint development project. Full Year 2022 Results Revenue for fiscal 2022 increased 17% to €983.7 million (approximately 13% on a constant currency basis), compared with the same period last year, driven by growth in both of the Company's business segments, the shift to high value solutions and favorable foreign currency translation. As expected, full-year revenue growth was partially offset by lower revenue from Covid-19, which accounted for 11% of revenue. Revenue from high value solutions was approximately 30% of full-year revenue, compared to 25% in 2021. For the full year 2022, strong revenue generation, favorable mix, and operating efficiencies led to a 110 basis point increase in gross profit margin of 32.5%, which was tempered by inflation. Operating profit margin improved to 19.6% for 2022. Franco Moro, Chief Executive Officer, stated, “We are pleased with a strong finish to 2022, thanks to the collective efforts of our employees worldwide. Over the last 18 months, we have worked alongside customers to address their growing need for high value solutions. With this added visibility, future capacity demand in the United States and Europe has outpaced our initial expectations. As a result, we are accelerating investment in the United States to meet our customers' most pressing needs and capitalize on this favorable demand. Concurrently, we are slowing the timing of our project in China to prioritize our expansion efforts in the U.S. and Italy." Biopharmaceutical and Diagnostic Solutions Segment (BDS) Revenue grew 25% to €231.5 million (approximately 21% on a constant currency basis), for the fourth quarter of 2022 and 15% to €799.7 million (approximately 11% on a constant currency basis) for the full year, compared with the same periods last year. Period-to-period increases were driven by growth in core drug containment products. For the fourth quarter of 2022, revenue from high value solutions increased to €87.2 million, while revenue from other containment and delivery solutions increased to €144.3 million. For the full year, revenue from high value solutions increased 41% to €293.2 million, while revenue from other containment and delivery solutions grew 4% to €506.4 million. Year-over-year gross profit margin expansion in the fourth quarter was driven by higher revenue, mix, better leverage from fixed costs and the recovery of inflationary costs. For the full year, the Company's growth, favorable mix shift, and operating efficiencies helped expand gross profit margin, which was also tempered by inflation. Operating profit margin in both the quarter and the fiscal year benefited from increases in other income. Engineering Segment Revenue increased 30% to €60.6 million for the fourth quarter of 2022 and was slightly ahead of expectations due to the timing and progression of projects. For the full year, revenue grew 23% to €184.0 million, compared with the same periods last year. For the fourth quarter of 2022, gross profit margin and operating profit margin decreased compared with the same period last year mostly due to project mix, but on a full-year basis both gross profit margin and operating profit margin improved mainly driven by contributions from more accretive business lines and ongoing optimization efforts to improve operational efficiencies. Balance Sheet and Cash Flow As of December 31, 2022, the Company had net cash of €46.0 million and cash and cash equivalents of €228.7 million. As expected, capital expenditures for the full year totaled €302.6 million, as the Company continued its investment in global expansion initiatives. For fiscal year 2022, cash generated from operating activities was €103.3 million, reflecting increased working capital needs to fund growth initiatives and higher levels of inventory to mitigate supply chain risk in the current environment. As expected, cash used for investing activities was €243.0 million and the main contributor to negative free cash flow of €137.0 million. New Order Intake and Backlog For the fourth quarter of 2022, new order intake totaled approximately €237 million, compared with €278 million in the same period last year. The Company ended the year with a committed backlog of approximately €957 million, a 9% increase over the same period last year, reflecting the expected decline in orders related to Covid-19. Excluding Covid-19, backlog increased 21%. Full Year 2023 Guidance The Company is introducing fiscal year 2023 guidance and expects: Revenue in the range of €1.085 billion to €1.115 billion, Adjusted diluted EPS in the range of €0.58 to €0.62, Adjusted EBITDA in the range of €290.5 million to €302.5 million. In addition, the Company expects that capital expenditures will range between 35% and 40% of revenue. Executive Chairman, Franco Stevanato, concluded, "With yet another year of consistent delivery against our financial objectives amid a favorable demand environment, we are well positioned to capitalize on increased customer demand and secular tailwinds to drive durable organic growth to create long-term shareholder value." Conference Call The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 2, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the “Financial Results” page under the Company's Investor Relations section of its website. Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the call using the following link: Webcast: A live, listen-only webcast of the call will be available at the following link: Dial in: Those who are unable to pre-register may dial in by calling: Italy: + 39 02 802 09 11 UK: + 44 1 212 818004 USA: +1 718 705 8796 USA Toll Free: +1 855 265 6958 Replay: The webcast will be archived for three months on the Company’s Investor Relations section of its website at: Forward-Looking Statements This press release may include forward-looking statements. The words "expects,” “establishing,” “future,” “accelerating,” “slowing,” “committed,” “expected,” “introducing,” “visibility,” “increased,” “well positioned,” “drive,” “create,” “growing,” “favorable,” and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S., its capital expenditure guidance, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company’s future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements. Non-GAAP Financial Information This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures. Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Net Profit, Adjusted Diluted EPS, Capital Employed, Net Cash, Free Cash Flow, and CAPEX. We believe that these non-GAAP financial measures provide useful and relevant information regarding our performance and improve our ability to assess our financial condition. While similar measures are widely used in the industry in which we operate, the financial measures we use may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS. About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: . Consolidated Income Statement (Amounts in € millions, except per share data) (Unaudited) For the three months For the years ended December 31, ended December 31, 2022 % 2021 % 2022 % 2021 % Revenue 292.1 100.0 % 232.6 100.0 % 983.7 100.0 % 843.9 100.0 % Costs of sales 191.9 65.7 % 159.6 68.6 % 663.9 67.5 % 578.5 68.6 % Gross Profit 100.2 34.3 % 73.0 31.4 % 319.8 32.5 % 265.4 31.4 % Other operating Income 6.7 2.3 % 2.2 0.9 % 18.8 1.9 % 9.4 1.1 % Selling and Marketing Expenses 8.3 2.8 % 4.4 1.9 % 26.1 2.7 % 20.4 2.4 % Research and Development Expenses 10.6 3.6 % 9.5 4.1 % 34.4 3.5 % 29.6 3.5 % General and Administrative Expenses 24.9 8.5 % 17.8 7.7 % 85.7 8.7 % 62.5 7.4 % Operating Profit 63.1 21.6 % 43.5 18.7 % 192.4 19.6 % 162.2 19.2 % Finance Income 7.8 2.7 % 15.3 6.6 % 25.0 2.5 % 21.7 2.6 % Finance Expense 7.1 2.4 % 5.1 2.2 % 29.8 3.0 % 18.8 2.2 % Share of Profit of an Associate — 0.0 % — 0.0 % — 0.0 % 0.5 0.1 % Profit Before Tax 63.8 21.9 % 53.7 23.1 % 187.6 19.1 % 165.7 19.6 % Income Taxes 15.5 5.3 % 9.1 3.9 % 44.6 4.5 % 31.4 3.7 % Net Profit 48.3 16.5 % 44.6 19.2 % 143.0 14.5 % 134.3 15.9 % Earnings per share Basic earnings per common share 0.18 0.17 0.54 0.53 Diluted earnings per common share 0.18 0.17 0.54 0.53 Average common shares outstanding 264.7 264.7 264.7 252.7 Average shares assuming dilution 264.7 264.7 264.7 252.7 Reported Segment Information (Amounts in € millions) (Unaudited) For the three months ended December 31, 2022 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 231.5 60.6 — 292.1 Inter-Segment 0.6 31.8 (32.4 ) — Revenue 232.1 92.4 (32.4 ) 292.1 Gross Profit 86.7 19.6 (6.1 ) 100.2 Gross Profit Margin 37.3 % 21.2 % 34.3 % Operating Profit 55.0 11.3 (3.2 ) 63.1 Operating Profit Margin 23.7 % 12.2 % 21.6 % For the three months ended December 31, 2021 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 185.9 46.7 — 232.6 Inter-Segment 0.3 29.7 (30.0 ) — Revenue 186.2 76.4 (30.0 ) 232.6 Gross Profit 61.1 16.6 (4.7 ) 73.0 Gross Profit Margin 32.8 % 21.7 % 31.4 % Operating Profit 37.9 10.9 (5.3 ) 43.5 Operating Profit Margin 20.3 % 14.3 % 18.7 % For the year ended December 31, 2022 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 799.7 184.0 — 983.7 Inter-Segment 1.5 115.5 (117.0 ) — Revenue 801.2 299.5 (117.0 ) 983.7 Gross Profit 274.9 64.7 (19.7 ) 319.8 Gross Profit Margin 34.3 % 21.6 % 32.5 % Operating Profit 182.6 41.3 (31.4 ) 192.4 Operating Profit Margin 22.8 % 13.8 % 19.6 % For the year ended December 31, 2021 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 694.0 149.9 — 843.9 Inter-Segment 1.1 69.0 (70.1 ) — Revenue 695.1 218.9 (70.1 ) 843.9 Gross Profit 229.9 42.2 (6.7 ) 265.4 Gross Profit Margin 33.1 % 19.3 % 31.4 % Operating Profit 149.0 22.9 (9.7 ) 162.2 Operating Profit Margin 21.4 % 10.5 % 19.2 % Cash Flow (Amounts in € millions) (Unaudited) For the three months ended December 31, For the years ended December 31, 2022 2021 2022 2021 Cash flow from operating activities 59.7 55.4 103.3 133.3 Cash flow used in investing activities (68.9 ) (21.1 ) (243.0 ) (96.4 ) Cash flow from/ (used in) financing activities (18.6 ) (52.4 ) (44.5 ) 254.8 Net change in cash and cash equivalents (27.8 ) (18.1 ) (184.2 ) 291.7 Non-U.S. GAAP Financial Information This press release contains non-U.S. GAAP financial measures. Please refer to "Non-U.S. GAAP Financial Information" and the tables included in this press release for a reconciliation of non-U.S. GAAP financial measures. Reconciliation of Revenue to Constant Currency Revenue (Amounts in € millions) (Unaudited) Three months ended December 31, 2022 Biopharmaceutical and Diagnostic Solutions Engineering Reported Revenue (IFRS GAAP) 231.5 60.6 Effect of changes in currency translation rates (7.1 ) 0.0 Organic Revenue (Non-IFRS GAAP) 224.4 60.6 Year ended December 31, 2022 Biopharmaceutical and Diagnostic Solutions Engineering Reported Revenue (IFRS GAAP) 799.7 184.0 Effect of changes in currency translation rates (27.0 ) 0.0 Organic Revenue (Non-IFRS GAAP) 772.7 184.0 Reconciliation of EBITDA (Amounts in € millions) (Unaudited) For the three months ended December 31, Change For the years ended December 31, Change 2022 2021 % 2022 2021 % Net Profit 48.3 44.6 8.3 % 143.0 134.3 6.5 % Income Taxes 15.5 9.1 70.3 % 44.6 31.4 42.1 % Finance Income (7.8 ) (15.3 ) (49.4 )% (25.0 ) (21.7 ) 15.4 % Finance Expenses 7.1 5.1 39.3 % 29.8 18.8 58.7 % Share of Profit of an Associate — — — (0.5 ) (100.0 )% Operating Profit 63.1 43.5 45.3 % 192.4 162.2 18.6 % Depreciation and Amortization 17.0 15.1 12.8 % 64.8 56.4 15.0 % EBITDA 80.2 58.6 36.9 % 257.3 218.6 17.7 % Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) (Unaudited) Three months ended December 31, 2022 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 80.2 63.1 15.5 48.3 0.18 Adjusting items: Start-up costs new plants (1) 1.6 1.6 0.4 1.2 0.01 Restructuring and related charges (2) 0.1 0.1 — 0.1 0.00 Adjusted 81.9 64.8 15.9 49.6 0.19 Adjusted Margin 28.0 % 22.2 % — — — Three months ended December 31, 2021 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 58.6 43.5 9.1 44.6 0.17 Adjusting items: — — — — 0.00 IPO costs (3) 0.1 0.1 0.0 0.1 0.00 Out-of-cycle bonus to personnel (4) (0.2 ) (0.2 ) (0.0 ) (0.1 ) 0.00 Start-up costs U.S. plant (1) 0.4 0.4 0.1 0.3 0.00 Gain from the sale of an associate (6) — — — (12.3 ) (0.05 ) Patent Box (7) — — 0.5 (0.5 ) 0.00 Provision for tax audit on previous years (8) — — (0.9 ) 0.9 0.01 Adjusted 58.9 43.8 8.8 33.0 0.13 Adjusted Margin 25.3 % 18.8 % — — — Year ended December 31, 2022 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 257.3 192.4 44.6 143.0 0.54 Adjusting items: Start-up costs new plants (1) 6.2 6.2 1.6 4.6 0.02 Restructuring and related charges (2) 0.1 0.1 — 0.1 0.00 Adjusted 263.6 198.7 46.2 147.7 0.56 Adjusted Margin 26.8 % 20.2 % — — — Year ended December 31, 2021 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 218.6 162.2 31.4 134.3 0.53 Adjusting items: — — — — — IPO costs (3) 0.8 0.8 0.2 0.6 0.00 Out-of-cycle bonus to personnel (4) 6.5 6.5 1.8 4.8 0.02 Foreign exchange loss for derivative on IPO proceeds (5) — — 1.0 3.3 0.01 Start-up costs U.S. plant (1) 1.1 1.1 0.3 0.8 0.00 Gain from the sale of an associate (6) — — — (12.3 ) (0.05 ) Patent Box (7) — — 7.6 (7.6 ) (0.03 ) Provision for tax audit on previous years (8) — — (0.9 ) 0.9 0.01 Restructuring and related charges (2) 1.2 1.2 0.3 0.8 0.01 Incentive Plans Settlement (9) (9.9 ) (9.9 ) (4.8 ) (5.1 ) (0.02 ) Adjusted 218.3 161.9 36.9 120.5 0.48 Adjusted Margin 25.9 % 19.2 % — — — (1) During the three months and the year ended December 31, 2022, the Group recorded respectively €1.6 million and €6.2 million respectively, of start-up costs for the new plant in Fishers, Indiana, United States, in Zhangjiagang, China, and in Latina, Italy. During the three months and the year ended December 31, 2021, the Group recorded respectively €0.4 million and €1.1 million of start-up costs to further the construction of the new plant in Fishers, Indiana, United States. (2) During the three months and the year ended December 31, 2022, the Group recorded €0.1 million in restructuring and related charges for the merger of Innoscan A/S into SVM Automatik A/S. During the year ended December 31, 2021, the Group recorded €1.2 million in restructuring and related charges for the consolidation of Balda plants in the U.S. (3) During the three months and the year ended December 31, 2021, the Group recorded €0.1 million and €0.8 million, respectively, in general and administrative expenses, relating to the listing of Stevanato Group S.p.A. ordinary shares on the NYSE. (4) During the year ended December 31, 2021, the Group granted a €6.5 million discretionary, out-of-cycle bonus to employees. During the three months ended December 31, 2021, the Group recorded €(0.2) million, of general and administrative expenses, mainly due to exchange rate impact and an adjustment of the estimation made as of September 30, 2021. No such bonuses were awarded or disbursed for the year ended December 31, 2022. (5) During the year ended December 31, 2021, the Group recorded €4.3 million, as foreign exchange loss for derivative on IPO proceeds. (6) During the three months and the year ended December 31, 2021 the Group recorded €12.3 million from the sale of a minority interest in the associate Swissfillon AG. (7) During the year ended December 31, 2021, the Group reached an agreement with the Italian Tax Agency regarding the so-called “Patent box regime”, resulting in a retroactive €7.6 million tax saving for the financial years 2016-2020. The tax benefit was accounted for as €7.1 million for the nine months ended September 30, 2021, based on our estimates. We accounted for a total accrual of €0.5 million for the three months ended December 31, 2021. (8) During the three months and the year ended December 31, 2021, the Group accrued €0.9 million related to a tax audit on fiscal year 2016. (9) During the year ended December 31, 2021, the Group recorded €9.9 million, in general and administrative expenses, as accrual reversal related to the early termination of incentive plans aimed at a limited number of key managers. Capital Employed (Amounts in € millions) (Unaudited) As of December 31, 2022 As of December 31, 2021 - Goodwill and Other intangible assets 79.4 79.2 - Right of Use assets 19.3 22.7 - Property, plant and equipment 641.4 392.7 - Financial assets - investments FVTPL 0.8 1.1 - Other non-current financial assets 1.0 1.3 - Deferred tax assets 69.2 55.9 Non-current assets 811.1 552.9 - Inventories 213.3 148.9 - Contract Assets 103.4 62.1 - Trade receivables 212.7 165.3 - Trade payables (239.2 ) (164.8 ) - Advances from customers (26.6 ) (23.6 ) - Contract Liabilities (14.8 ) (18.8 ) Trade working capital 248.8 169.1 - Tax receivables and Other receivables 54.0 51.4 - Tax payables and Other liabilities (111.1 ) (85.3 ) Net working capital 191.7 135.3 - Deferred tax liabilities (21.0 ) (19.1 ) - Employees benefits (8.3 ) (11.9 ) - Provisions (5.5 ) (3.5 ) - Other non-current liabilities (18.1 ) (1.8 ) Total non-current liabilities and provisions (52.9 ) (36.3 ) Capital employed 949.9 651.9 Net cash/ (debt) 46.0 189.8 Equity (995.9 ) (841.7 ) Total equity and net debt (949.9 ) (651.9 ) Free Cash Flow (Amounts in € millions) (Unaudited) For the three months ended December 31, For the years ended December 31, 2022 2021 2022 2021 Cash Flow from Operating Activities 59.7 55.4 103.3 133.3 Interest paid 1.0 1.3 3.5 4.4 Interest received (0.3 ) (0.2 ) (0.8 ) (0.6 ) Purchase of property, plant and equipment (67.9 ) (36.3 ) (235.0 ) (107.7 ) Proceeds from sale of property, plant and equipment (0.4 ) 1.2 0.1 1.2 Purchase of intangible assets (0.3 ) (2.1 ) (8.1 ) (5.5 ) Free Cash Flow (8.2 ) 19.3 (137.0 ) 25.1 Net Cash (Amounts in € millions) (Unaudited) As of December 31, As of December 31, 2022 2021 Non-current financial liabilities (148.4 ) (202.3 ) Current financial liabilities (70.7 ) (46.2 ) Other non-current financial assets - Derivatives 2.8 — Other current financial assets 33.6 27.2 Cash and cash equivalents 228.7 411.0 Net Cash/ (Debt) 46.0 189.8 CAPEX (Amounts in € millions) For the year ended December 31, Change 2022 2021 € Addition to Property, plants and equipment 294.5 116.6 177.9 Addition to Intangible Assets 8.1 5.5 2.6 CAPEX 302.6 122.1 180.5 Reconciliation of 2023 Guidance Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) (Unaudited) Revenue EBITDA Operating Profit Net Profit Diluted EPS Reported 1,085.0 - 1,115.0 281.3 - 293.3 199.9 - 211.9 147.8 - 156.9 0.56 - 0.59 Adjusting items: Start-up costs new plants 9.1 9.1 6.8 0.03 Adjusted 1,085.0 - 1,115.0 290.5 - 302.5 209.0 - 221.0 154.6 - 163.7 0.58 - 0.62